[
  {
    "ts": null,
    "headline": "Novo Nordisk's New Diabetes Drug Outshines Ozempic: Is The Stock a Buy?",
    "summary": "Novo Nordisk's plan to gain ground in the GLP-1 space is slowly taking shape.",
    "url": "https://finnhub.io/api/news?id=d3cfd0c3216bd28ac56f69e850476c0799dd7e694df654b8bd8fb4c325cd862d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771275900,
      "headline": "Novo Nordisk's New Diabetes Drug Outshines Ozempic: Is The Stock a Buy?",
      "id": 139117432,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk's plan to gain ground in the GLP-1 space is slowly taking shape.",
      "url": "https://finnhub.io/api/news?id=d3cfd0c3216bd28ac56f69e850476c0799dd7e694df654b8bd8fb4c325cd862d"
    }
  },
  {
    "ts": null,
    "headline": "Liberty One Cuts Its Lamb Weston Position in Half With $32 Million Sale",
    "summary": "Lamb Weston is a global leader in frozen potato products, serving both retail and foodservice markets with a diversified brand portfolio.",
    "url": "https://finnhub.io/api/news?id=c6be90d392e1cda47398c81b3b55efa4a621c7fdd6169869207d92c292e09fee",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771269482,
      "headline": "Liberty One Cuts Its Lamb Weston Position in Half With $32 Million Sale",
      "id": 139116628,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lamb Weston is a global leader in frozen potato products, serving both retail and foodservice markets with a diversified brand portfolio.",
      "url": "https://finnhub.io/api/news?id=c6be90d392e1cda47398c81b3b55efa4a621c7fdd6169869207d92c292e09fee"
    }
  },
  {
    "ts": null,
    "headline": "Why Eli Lilly’s $1 Billion AI Bet Could Reshape Drug Discovery",
    "summary": "As of February 13, 2026, shares of Eli Lilly (NYSE:LLY) were trading at $1,040, just 5.8% below the stock’s all-time high. Retail sentiment has turned decisively bullish following the company’s Q4 2025 earnings beat, with Reddit’s sentiment score climbing from neutral (57.3) to bullish (65.7) over the past week. The catalyst? Eli Lilly overdelivered on ... Why Eli Lilly’s $1 Billion AI Bet Could Reshape Drug Discovery",
    "url": "https://finnhub.io/api/news?id=b23238c2ac72c69d13714e4a8eff981ceaf05465a36d93dfd7a5ac520c82b656",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771268419,
      "headline": "Why Eli Lilly’s $1 Billion AI Bet Could Reshape Drug Discovery",
      "id": 139117399,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "As of February 13, 2026, shares of Eli Lilly (NYSE:LLY) were trading at $1,040, just 5.8% below the stock’s all-time high. Retail sentiment has turned decisively bullish following the company’s Q4 2025 earnings beat, with Reddit’s sentiment score climbing from neutral (57.3) to bullish (65.7) over the past week. The catalyst? Eli Lilly overdelivered on ... Why Eli Lilly’s $1 Billion AI Bet Could Reshape Drug Discovery",
      "url": "https://finnhub.io/api/news?id=b23238c2ac72c69d13714e4a8eff981ceaf05465a36d93dfd7a5ac520c82b656"
    }
  },
  {
    "ts": null,
    "headline": "JPMorgan builds $2.93 billion stake in health care stock",
    "summary": "JPMorgan Chase just planted a massive $2.93 billion flag in perhaps one of the hottest corners of the market. The big bank’s investment arm disclosed a whopping multibillion-dollar stake in Eli Lilly (LLY) in its fresh 13F filing, making it the stand-out addition in its power-packed portfolio. The ...",
    "url": "https://finnhub.io/api/news?id=5d7a212c00eedb5098b5aeaf8e0f830d1bec814c37a1bcc20d8a1bc0e8d5872a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771264020,
      "headline": "JPMorgan builds $2.93 billion stake in health care stock",
      "id": 139115745,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "JPMorgan Chase just planted a massive $2.93 billion flag in perhaps one of the hottest corners of the market. The big bank’s investment arm disclosed a whopping multibillion-dollar stake in Eli Lilly (LLY) in its fresh 13F filing, making it the stand-out addition in its power-packed portfolio. The ...",
      "url": "https://finnhub.io/api/news?id=5d7a212c00eedb5098b5aeaf8e0f830d1bec814c37a1bcc20d8a1bc0e8d5872a"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly builds orforglipron cache to avoid previous GLP-1RA shortages",
    "summary": "Lilly’s amassing of a $1.5bn pre-launch inventory follows sizeable investments into US manufacturing facilities.",
    "url": "https://finnhub.io/api/news?id=31f5a34f2fa66ff98e6e4db66bbd317d0688ff08f3e9f5e1cd0fc3fc2ed4aafc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771261337,
      "headline": "Eli Lilly builds orforglipron cache to avoid previous GLP-1RA shortages",
      "id": 139115746,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly’s amassing of a $1.5bn pre-launch inventory follows sizeable investments into US manufacturing facilities.",
      "url": "https://finnhub.io/api/news?id=31f5a34f2fa66ff98e6e4db66bbd317d0688ff08f3e9f5e1cd0fc3fc2ed4aafc"
    }
  },
  {
    "ts": null,
    "headline": "NVO Crashes 21% in a Month: Is This an Indication to Sell the Stock?",
    "summary": "Novo Nordisk stock sinks 21% in a month as weak 2026 guidance, slowing semaglutide sales, and rising competition overshadow relatively strong Q4 results.",
    "url": "https://finnhub.io/api/news?id=1a5895678bc673699d2743c2aa2cd28a69eb9c0df64ca5fdbb2a065f427c85a2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771255560,
      "headline": "NVO Crashes 21% in a Month: Is This an Indication to Sell the Stock?",
      "id": 139115747,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk stock sinks 21% in a month as weak 2026 guidance, slowing semaglutide sales, and rising competition overshadow relatively strong Q4 results.",
      "url": "https://finnhub.io/api/news?id=1a5895678bc673699d2743c2aa2cd28a69eb9c0df64ca5fdbb2a065f427c85a2"
    }
  },
  {
    "ts": null,
    "headline": "Lilly to participate in TD Cowen's 46th Annual Health Care Conference",
    "summary": "Eli Lilly and Company (NYSE:LLY) will participate in TD Cowen's 46th Annual Health Care Conference on March 2, 2026. Lucas Montarce, executive vice president and chief financial officer, will take part in a fireside chat at 3:10 p.m., Eastern time.",
    "url": "https://finnhub.io/api/news?id=057fb5eecceec76c66c1f9e86804c0821e6baf903341d62acb662972e20a485b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771254000,
      "headline": "Lilly to participate in TD Cowen's 46th Annual Health Care Conference",
      "id": 139114926,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) will participate in TD Cowen's 46th Annual Health Care Conference on March 2, 2026. Lucas Montarce, executive vice president and chief financial officer, will take part in a fireside chat at 3:10 p.m., Eastern time.",
      "url": "https://finnhub.io/api/news?id=057fb5eecceec76c66c1f9e86804c0821e6baf903341d62acb662972e20a485b"
    }
  },
  {
    "ts": null,
    "headline": "How Investors Are Reacting To Eli Lilly (LLY) Building Massive Orforglipron Inventory After Strong 2025 Results",
    "summary": "Eli Lilly and Company recently reported strong 2025 results, with full-year sales of US$65.18 billion, net income of US$20.64 billion, and completed a US$4.08 billion share repurchase program covering 4.76 million shares. The company is reinforcing its leadership in diabetes and obesity care by projecting 2026 revenue of US$80–83 billion and preparing a very large pre-launch inventory for its oral GLP-1 pill orforglipron ahead of potential approval. We’ll now examine how Eli Lilly’s...",
    "url": "https://finnhub.io/api/news?id=05c70517d6f3d38eb54418f83ab3408e16ddf0b92e583f6d51109d8032d78502",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771251084,
      "headline": "How Investors Are Reacting To Eli Lilly (LLY) Building Massive Orforglipron Inventory After Strong 2025 Results",
      "id": 139114927,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company recently reported strong 2025 results, with full-year sales of US$65.18 billion, net income of US$20.64 billion, and completed a US$4.08 billion share repurchase program covering 4.76 million shares. The company is reinforcing its leadership in diabetes and obesity care by projecting 2026 revenue of US$80–83 billion and preparing a very large pre-launch inventory for its oral GLP-1 pill orforglipron ahead of potential approval. We’ll now examine how Eli Lilly’s...",
      "url": "https://finnhub.io/api/news?id=05c70517d6f3d38eb54418f83ab3408e16ddf0b92e583f6d51109d8032d78502"
    }
  },
  {
    "ts": null,
    "headline": "RIGL Stock Rises 59% in a Year: Time to Buy, Hold or Sell?",
    "summary": "Rigel Pharmaceuticals climbs 59% in a year as Tavalisse anchors growth, oncology gains traction and 2026 guidance points to sustained momentum.",
    "url": "https://finnhub.io/api/news?id=b97ffd9f980a2dae748aaf6c371aa0150313c7ece975ff7dc1e05000bd6f1819",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771250340,
      "headline": "RIGL Stock Rises 59% in a Year: Time to Buy, Hold or Sell?",
      "id": 139115748,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Rigel Pharmaceuticals climbs 59% in a year as Tavalisse anchors growth, oncology gains traction and 2026 guidance points to sustained momentum.",
      "url": "https://finnhub.io/api/news?id=b97ffd9f980a2dae748aaf6c371aa0150313c7ece975ff7dc1e05000bd6f1819"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Expands Beyond GLP-1 With RNA Cancer AI And Obesity Bets",
    "summary": "Eli Lilly (NYSE:LLY) announced the acquisition of Orna Therapeutics to expand into circular RNA based gene and autoimmune therapies. The company reported positive Phase 3 results for Retevmo in early stage non small cell lung cancer. Lilly highlighted efforts in AI powered drug development and preparations for a major launch of its oral weight loss drug, orforglipron. Eli Lilly, best known for its diabetes and obesity treatments, is pushing further into oncology, RNA based medicines, and AI...",
    "url": "https://finnhub.io/api/news?id=7101d021a7c0b82500d2b5c59db4149b1288a66a0b7d95676e3211b59b8bd7cc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771247486,
      "headline": "Eli Lilly Expands Beyond GLP-1 With RNA Cancer AI And Obesity Bets",
      "id": 139114137,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (NYSE:LLY) announced the acquisition of Orna Therapeutics to expand into circular RNA based gene and autoimmune therapies. The company reported positive Phase 3 results for Retevmo in early stage non small cell lung cancer. Lilly highlighted efforts in AI powered drug development and preparations for a major launch of its oral weight loss drug, orforglipron. Eli Lilly, best known for its diabetes and obesity treatments, is pushing further into oncology, RNA based medicines, and AI...",
      "url": "https://finnhub.io/api/news?id=7101d021a7c0b82500d2b5c59db4149b1288a66a0b7d95676e3211b59b8bd7cc"
    }
  },
  {
    "ts": null,
    "headline": "AI is disrupting drug discovery faster than expected",
    "summary": "Opening Bid Unfiltered is available on Apple Podcasts, Spotify, YouTube, or wherever you get your podcasts. If you aren’t paying attention to the companies behind a new wave of AI-driven drug development, you may end up missing out on essential investment opportunities. One company that has caught our attention is Chai Discovery, founded in 2024 by co-founder Joshua Meier. After graduating from Harvard, Meier began working as a researcher at OpenAI (OPAI.PVT) during the development of GPT-1 and GPT-2. He then worked at Meta's generative biology group, where he co-led the development of ESM1, the first transformer protein-language model. Chai Discovery is currently one of the buzziest startups in AI drug development. In December, the company completed a Series B funding round, raising an additional $130 million at a valuation of $1.3 billion, cementing its unicorn status. Backers include Silicon Valley heavyweights such as General Catalyst and OpenAI. The company also recently inked a deal with Eli Lilly (LLY), under which the drug giant will use Chai’s models. Yahoo Finance Executive Editor Brian Sozzi sits down with Meier on Opening Bid Unfiltered to go inside the world of AI-driven medicine. Listen on your favorite podcast platform or watch on our website for full episodes of Opening Bid Unfiltered. Yahoo Finance's Opening Bid Unfiltered is produced by Langston Sessoms.",
    "url": "https://finnhub.io/api/news?id=e9cf9332db4d48264d22a0c7935706af1d88b7f87c2959c1559e9a53878ca56c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771246819,
      "headline": "AI is disrupting drug discovery faster than expected",
      "id": 139114133,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Opening Bid Unfiltered is available on Apple Podcasts, Spotify, YouTube, or wherever you get your podcasts. If you aren’t paying attention to the companies behind a new wave of AI-driven drug development, you may end up missing out on essential investment opportunities. One company that has caught our attention is Chai Discovery, founded in 2024 by co-founder Joshua Meier. After graduating from Harvard, Meier began working as a researcher at OpenAI (OPAI.PVT) during the development of GPT-1 and GPT-2. He then worked at Meta's generative biology group, where he co-led the development of ESM1, the first transformer protein-language model. Chai Discovery is currently one of the buzziest startups in AI drug development. In December, the company completed a Series B funding round, raising an additional $130 million at a valuation of $1.3 billion, cementing its unicorn status. Backers include Silicon Valley heavyweights such as General Catalyst and OpenAI. The company also recently inked a deal with Eli Lilly (LLY), under which the drug giant will use Chai’s models. Yahoo Finance Executive Editor Brian Sozzi sits down with Meier on Opening Bid Unfiltered to go inside the world of AI-driven medicine. Listen on your favorite podcast platform or watch on our website for full episodes of Opening Bid Unfiltered. Yahoo Finance's Opening Bid Unfiltered is produced by Langston Sessoms.",
      "url": "https://finnhub.io/api/news?id=e9cf9332db4d48264d22a0c7935706af1d88b7f87c2959c1559e9a53878ca56c"
    }
  },
  {
    "ts": null,
    "headline": "USOPC Announces the Team USA Athlete Recovery Program in Partnership with Eli Lilly and Company",
    "summary": "The United States Olympic & Paralympic Committee (USOPC) today announced the Team USA Athlete Recovery Program in partnership with Lilly, reinforcing a shared commitment across multiple years to fostering athlete health, recovery, and well-being beyond competition.",
    "url": "https://finnhub.io/api/news?id=4aab1ad3df06d6abe3b834ab699a604499a78dbf413738060f5b77ff68185f75",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771246800,
      "headline": "USOPC Announces the Team USA Athlete Recovery Program in Partnership with Eli Lilly and Company",
      "id": 139114139,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The United States Olympic & Paralympic Committee (USOPC) today announced the Team USA Athlete Recovery Program in partnership with Lilly, reinforcing a shared commitment across multiple years to fostering athlete health, recovery, and well-being beyond competition.",
      "url": "https://finnhub.io/api/news?id=4aab1ad3df06d6abe3b834ab699a604499a78dbf413738060f5b77ff68185f75"
    }
  },
  {
    "ts": null,
    "headline": "Lilly's Retevmo (selpercatinib) delivers substantial event-free survival benefit as an adjuvant therapy in early-stage RET fusion-positive lung cancer",
    "summary": "Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 LIBRETTO-432 clinical trial of Retevmo (selpercatinib) as adjuvant therapy versus placebo. The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in investigator-assessed event-free survival (EFS) in patients with early-stage (II-IIIA) rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC).",
    "url": "https://finnhub.io/api/news?id=f306bab4a80190cb6b664ff05c40bddb30d557307802121b7c9d194749e7361b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771242300,
      "headline": "Lilly's Retevmo (selpercatinib) delivers substantial event-free survival benefit as an adjuvant therapy in early-stage RET fusion-positive lung cancer",
      "id": 139113374,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 LIBRETTO-432 clinical trial of Retevmo (selpercatinib) as adjuvant therapy versus placebo. The study met its primary endpoint, demonstrating a highly statistically significant and clinically meaningful improvement in investigator-assessed event-free survival (EFS) in patients with early-stage (II-IIIA) rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC).",
      "url": "https://finnhub.io/api/news?id=f306bab4a80190cb6b664ff05c40bddb30d557307802121b7c9d194749e7361b"
    }
  },
  {
    "ts": null,
    "headline": "Zura Bio Highlights Key Phase 2 Tibulizumab Readouts at Guggenheim Biotech Summit 2026",
    "summary": "Zura Bio (NASDAQ:ZURA) outlined its near-term clinical milestones and strategy at Guggenheim Securities’ Emerging Outlook Biotech Summit 2026, emphasizing upcoming Phase 2 readouts for its lead bispecific antibody, tibulizumab, in autoimmune and inflammatory diseases. New CEO highlights shift towar",
    "url": "https://finnhub.io/api/news?id=1dd29595d70bf320232cb0d3ec1347211659263406f47f22d87e89fe9e0ad135",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771239790,
      "headline": "Zura Bio Highlights Key Phase 2 Tibulizumab Readouts at Guggenheim Biotech Summit 2026",
      "id": 139113375,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Zura Bio (NASDAQ:ZURA) outlined its near-term clinical milestones and strategy at Guggenheim Securities’ Emerging Outlook Biotech Summit 2026, emphasizing upcoming Phase 2 readouts for its lead bispecific antibody, tibulizumab, in autoimmune and inflammatory diseases. New CEO highlights shift towar",
      "url": "https://finnhub.io/api/news?id=1dd29595d70bf320232cb0d3ec1347211659263406f47f22d87e89fe9e0ad135"
    }
  },
  {
    "ts": null,
    "headline": "Impax U.S. Sustainable Economy Fund Q4 2025 Contributors And Detractors",
    "summary": "Eli Lilly is included due to its strategic positioning with respect to sustainability opportunities, specifically in HealthCare Access and Innovation. Read more here.",
    "url": "https://finnhub.io/api/news?id=07667a0428aedcbe0898bb0e79c2f2bdd85d941f2d841119e25a5e092ac33995",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771239480,
      "headline": "Impax U.S. Sustainable Economy Fund Q4 2025 Contributors And Detractors",
      "id": 139115065,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2191628799/image_2191628799.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Eli Lilly is included due to its strategic positioning with respect to sustainability opportunities, specifically in HealthCare Access and Innovation. Read more here.",
      "url": "https://finnhub.io/api/news?id=07667a0428aedcbe0898bb0e79c2f2bdd85d941f2d841119e25a5e092ac33995"
    }
  },
  {
    "ts": null,
    "headline": "Theranostics earmarked as “the future” of radiopharmaceuticals",
    "summary": "As RLTs and theranostics gain prevalence, companies must consider how to overcome their associated regulatory, manufacturing and reimbursement hurdles.",
    "url": "https://finnhub.io/api/news?id=42dc355fe9c2aba8a6bdb17b008a2dc221790295e37a66d7cf9aaec99105950b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771236000,
      "headline": "Theranostics earmarked as “the future” of radiopharmaceuticals",
      "id": 139116629,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "As RLTs and theranostics gain prevalence, companies must consider how to overcome their associated regulatory, manufacturing and reimbursement hurdles.",
      "url": "https://finnhub.io/api/news?id=42dc355fe9c2aba8a6bdb17b008a2dc221790295e37a66d7cf9aaec99105950b"
    }
  }
]